14.2 Combined Hormonal Contraception
Key Takeaways
- Migraine with aura at any age is US MEC Category 4 for combined hormonal contraception because of a 2- to 4-fold increase in ischemic stroke risk.
- Age 35 or older combined with smoking 15 or more cigarettes daily is Category 4, while fewer than 15 cigarettes daily is Category 3.
- Severe hypertension at 160 systolic or 100 diastolic or above is Category 4, while 140 to 159 or 90 to 99 is Category 3.
- Known thrombogenic mutations, current or past venous thromboembolism, ischemic heart disease, and stroke are all Category 4.
- Estrogen raises hepatic synthesis of fibrinogen and factors VII, VIII, and X while lowering antithrombin III, which is the mechanism behind every venous restriction.
Combined Hormonal Contraceptives (CHCs)
Combined hormonal contraceptives contain both a synthetic estrogen (ethinyl estradiol [EE], estetrol, or estradiol valerate) and a synthetic progestin. Available delivery formulations include combined oral contraceptive pills (COCs), the transdermal patch, and contraceptive vaginal rings.
Mechanisms of Action
- Estrogen Component: Provides negative feedback on the anterior pituitary gland, suppressing the secretion of Follicle Stimulating Hormone (FSH). This prevents ovarian follicular recruitment and dominant follicle selection. Estrogen also stabilizes the endometrial vascular bed to maintain cycle control and prevent breakthrough bleeding.
- Progestin Component: Suppresses the hypothalamic-pituitary axis to block the mid-cycle Luteinizing Hormone (LH) surge, thereby reliably inhibiting ovulation. Progestin thickens cervical mucus to block sperm penetration and alters endometrial histology, creating an atrophic environment hostile to implantation.
Absolute Contraindications (US MEC Category 4)
| Clinical Condition | US MEC Category | Pathophysiological Rationale & High-Yield AMCB Rule |
|---|---|---|
| Age ≥35 Years AND Smoking ≥15 Cigarettes/Day | Category 4 | Marked synergistic increase in arterial thrombosis, acute myocardial infarction, and ischemic stroke. (If <15 cigarettes/day: Category 3). |
| Severe Hypertension (SBP ≥160 or DBP ≥100 mmHg) | Category 4 | Dramatically elevates stroke and myocardial infarction risk. (If SBP 140–159 or DBP 90–99 mmHg: Category 3). |
| Migraine with Aura (At Any Age) | Category 4 | History of focal neurological symptoms (scintillating scotomas, visual hemianopsia, unilateral paresthesias) elevates ischemic stroke risk 2- to 4-fold; ethinyl estradiol further compounds arterial stroke risk. |
| Current or Past Deep Vein Thrombosis (DVT) / Pulmonary Embolism (PE) | Category 4 | Estrogen stimulates hepatic synthesis of clotting factors (fibrinogen, factors VII, VIII, X) and decreases antithrombin III, markedly elevating recurrent VTE risk. |
| Known Thrombogenic Mutations | Category 4 | Factor V Leiden, Prothrombin G20210A mutation, Antithrombin III, Protein C, or Protein S deficiency. |
| Ischemic Heart Disease or Cerebrovascular Accident (CVA) | Category 4 | High risk of recurrent coronary or cerebral vascular occlusion. |
| Current Breast Cancer (or Past History Within 5 Years) | Category 4 | Estrogen- and progestin-sensitive malignancy. Hormonal stimulation can accelerate tumor progression. (All hormonal methods are Category 4). |
| Diabetes Mellitus with Microvascular Disease or Duration >20 Years | Category 4 | Presence of nephropathy, retinopathy, neuropathy, or advanced vascular damage accelerates arterial thrombosis risk. |
| Severe Decompensated Cirrhosis, Hepatic Adenoma, or Hepatoma | Category 4 | Steroid hormones are metabolized hepatically; impaired clearance leads to accumulation, and hormones promote hepatic adenoma expansion/rupture. |
| Postpartum <21 Days (Regardless of Breastfeeding) | Category 4 | Baseline early puerperium represents a profound hypercoagulable state with markedly elevated venous thromboembolism risk. |
Missed Pill Management Protocols (CDC Selected Practice Recommendations)
- 1 Missed Active COC Pill (<48 Hours Since Last Dose):
- Take the missed pill as soon as remembered.
- Take the next pill at the usual scheduled time (even if this means taking 2 pills on the same day).
- No back-up contraception is required. Emergency contraception is not indicated unless pills were missed earlier in the cycle.
- ≥2 Missed Active COC Pills (≥48 Hours Since Last Dose):
- Take the most recent missed pill immediately; discard any other previously missed pills.
- Continue taking remaining active pills at the usual scheduled time.
- Use back-up barrier contraception (or abstain from intercourse) for 7 consecutive days.
- If pills were missed during Week 1 (Days 1–7): Recommend emergency contraception if unprotected coitus occurred in the previous 5 days.
- If pills were missed during Week 3 (Days 15–21): Complete all active pills in the current pack, OMIT the 7-day placebo/hormone-free interval, and start a brand-new pack of active pills the very next day.
Transdermal Patch & Vaginal Ring Specifics
- Transdermal Patch (Norelgestromin / EE [Xulane, Zafemy] or Levonorgestrel / EE [Twirla]): Applied weekly for 3 consecutive weeks, followed by 1 patch-free week. Steady-state estrogen exposure is higher than with 30 mcg COCs. Reduced efficacy and elevated VTE risk in individuals weighing ≥90 kg (≥198 lbs) or BMI ≥30 kg/m² (Twirla is contraindicated in BMI ≥30 kg/m²).
- Vaginal Rings:
- Etonogestrel / EE (NuvaRing): Inserted into vagina for 3 weeks, removed for 1 ring-free week. If expelled for >3 hours, reinsert and use back-up contraception for 7 days.
- Segesterone Acetate / EE (Annovera): Single reusable ring used for 13 full cycles (inserted for 21 days, removed for 7 days, washed, and reinserted each cycle for 1 full year).
Effectiveness, Initiation & Backup Rules
All three combined delivery systems share one effectiveness profile, because they share one failure mode — user adherence, not pharmacology. Typical-use failure is about 7 pregnancies per 100 users in the first year, against about 0.3 per 100 with perfect use. That 20-fold gap between perfect and typical use is the whole clinical argument for offering long-acting reversible contraception alongside a pill request rather than only after the pill has failed.
Initiation and correction rules come from the 2024 US Selected Practice Recommendations (US SPR):
- CHC may be started on any day once reasonable certainty of no pregnancy is established ("Quick Start"). Waiting for the next menses is a convenience, never a safety requirement, and sending a patient away to wait is a documented cause of unintended pregnancy.
- Started within the first 5 days of menstrual bleeding: no backup needed.
- Started at any other time: abstain or use barrier protection for 7 days.
- Patch detached or ring out of place for less than 48 hours: replace as soon as possible; no backup needed.
- 48 hours or more: replace, then abstain or use barriers until the method has been used correctly for 7 consecutive days, and consider emergency contraception if the lapse fell in or adjacent to the hormone-free interval.
Notice the internal logic that makes all of these memorable: seven days of consistent hormone re-establishes ovulation suppression, and a lapse matters most when it lengthens the hormone-free interval, because that is when a follicle can escape.
Non-Contraceptive Benefits
These change the risk–benefit calculation for an ambivalent patient and appear constantly in counseling stems:
- Ovarian cancer risk falls by roughly 20% for every 5 years of use, approaching a halving with long-term use, and the protection persists for decades after stopping.
- Endometrial cancer risk falls by roughly a quarter for every 5 years of use, again durable after discontinuation.
- Reliable improvement in dysmenorrhea, heavy menstrual bleeding and the resulting iron-deficiency anemia, acne and hirsutism, functional ovarian cysts, and ectopic pregnancy risk. Extended and continuous regimens are first-line medical therapy for endometriosis-associated pain.
- CHC confers no protection against sexually transmitted infection. Every CHC visit therefore includes condom counseling; the two methods answer different questions.
Extended and Continuous Regimens
The 21/7 cycle is a design artifact intended to reassure mid-century users, not a physiologic requirement — the withdrawal bleed on placebo days is not a menstrual period and has no health benefit. Extended regimens (for example 84 active pills followed by 7 hormone-free or low-dose-estrogen days) and continuous regimens (active hormone with no scheduled withdrawal bleed) are appropriate for menstrual suppression, catamenial migraine without aura, endometriosis, anemia, and simple patient preference. Counsel explicitly that unscheduled breakthrough bleeding is expected in the first 3 to 6 months and is not a sign of method failure; it usually settles with continued use, and premature discontinuation for this reason is a common avoidable outcome.
Drug Interactions That Reduce Efficacy
| Interacting agent | Effect | US MEC |
|---|---|---|
| Rifampin, rifabutin | Potent CYP3A4 induction lowers contraceptive steroid levels | Category 3 |
| Phenytoin, carbamazepine, barbiturates, primidone, topiramate, oxcarbazepine | Hepatic enzyme induction lowers efficacy | Category 3 |
| Lamotrigine | Interaction runs the other direction — estrogen lowers lamotrigine levels and risks seizure breakthrough, then levels rebound during the hormone-free week | Category 3 |
| Ritonavir-boosted protease inhibitors | Lower contraceptive steroid levels | Category 3 |
| Broad-spectrum antibiotics other than the rifamycins | No clinically meaningful interaction | Category 1 |
The last row is the highest-yield line in the table. A patient prescribed doxycycline, amoxicillin, or nitrofurantoin does not need backup contraception for the antibiotic itself — a persistent myth that still appears in patient handouts. The rifamycins are the exception that created the rule.
Warning Signs: ACHES
Teach every patient starting a combined method the ACHES mnemonic together with the instruction to seek care the same day:
- A — Abdominal pain that is severe: hepatic adenoma, or mesenteric or pelvic vein thrombosis.
- C — Chest pain, shortness of breath, or hemoptysis: pulmonary embolism or myocardial infarction.
- H — Headache that is severe, new in character, or accompanied by focal neurologic signs: stroke, or new-onset migraine with aura, which converts the method to Category 4 and requires stopping it.
- E — Eye problems: sudden visual loss, visual field defect, or diplopia.
- S — Severe leg pain, especially unilateral calf swelling, warmth, or tenderness: deep vein thrombosis.
Every letter maps back to the same pathophysiology already established above — estrogen-driven arterial or venous thrombosis, or hepatic steroid handling. If a candidate can reconstruct the mechanism, the mnemonic becomes a checklist rather than a list to memorize.
A 37-year-old G2P2 presents to discuss contraceptive options. Her medical history is notable for migraine headaches with visual aura consisting of scintillating scotomas and hemianopsia occurring 1 to 2 times monthly. She does not smoke cigarettes. Her blood pressure is 118/76 mmHg and BMI is 23 kg/m². She requests a highly effective contraceptive method and asks about starting a combined oral contraceptive (COC) pill. Under the CDC Medical Eligibility Criteria for Contraceptive Use (US MEC), what is the classification of combined hormonal contraceptives for this patient, and which alternative method is the safest, most effective choice?